Treatment-related Hypertension as a Prognostic Factor for De Novo Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Real-world Evidence Study
In this report, we examined the outcomes of patients with metastatic hormone-sensitive prostate cancer and their correlation with hypertension toxicities. We found that patients who developed clinically significant blood pressure toxicity early in oncological treatment experienced longer survival.
Authors
- Sara Merler (ORCID: https://orcid.org/0000-0002-8691-6284)
- Silke Gillessen (ORCID: https://orcid.org/0000-0001-5746-6555)
- Fabio Turco (ORCID: https://orcid.org/0000-0003-3111-7888)
- Lorenzo Ruinelli (ORCID: https://orcid.org/0000-0002-9144-2570)
- Luca Gabutti (ORCID: https://orcid.org/0000-0002-1929-6759)
- Martino Pedrani (ORCID: https://orcid.org/0000-0002-8502-8226)
- Ursula Vogl (ORCID: https://orcid.org/0000-0002-2046-4246)
- Ricardo Pereira Mestre (ORCID: https://orcid.org/0000-0002-3123-3697)
- Vasile Urechie
- Irene Testi
- Selin Candan
- Luís Castelo-Branco (ORCID: https://orcid.org/0000-0002-3967-530X)
- Luigi Tortola (ORCID: https://orcid.org/0000-0002-8480-2080)
- Giuseppe Salfi (ORCID: https://orcid.org/0000-0003-4953-0339)
- Amos Colombo (ORCID: https://orcid.org/0009-0000-3638-8973)
Institutions
- University of Verona (IT)
- University of Parma (IT)
- University of Milan (IT)
- Ente Ospedaliero Cantonale (CH)
- Institute of Oncology Research (CH)
- Università della Svizzera italiana (CH)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- European Urology Open Science
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1016/j.euros.2024.10.023
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00